Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:30 AM ET 8-K
Leadership Change Phillips 66 PSX

Phillips 66 Leadership Change

Richard G. Harbison, Executive Vice President of Refining at Phillips 66, has provided notice of his intention to retire from the company. His retirement is scheduled to become effective on December 31, 2026.

8:30 AM ET 8-K
Clinical Trial Data Coya Therapeutics, Inc. COYA

Coya Therapeutics Clinical Trial Data

Coya Therapeutics announced it has achieved full enrollment of 120 patients in its Phase 2/3 ALSTARS trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The company expects to release topline data from the double-blind treatment phase in early Q2 2027.

8:30 AM ET 8-K
Other 8-K Filing Immunome Inc. IMNM

Immunome Other 8-K Filing

Immunome entered into an amendment with Bristol-Myers Squibb (BMS) to eliminate all future milestone and royalty payment obligations related to varegacestat and AL101. In exchange, Immunome paid BMS $20 million in cash and issued approximately 4.4 million shares of common stock, while also gaining full ownership of the related patent rights.

Counterparty
Bristol-Myers Squibb Company
8:22 AM ET 8-K
Partnership Leidos Holdings, Inc. LDOS

Leidos Holdings Partnership with Altaris, LLC

Leidos and investment firm Altaris completed the formation of a joint venture named Nickel JV Ultimate Parent, LLC (operating under the Analogic brand) by combining Leidos' Security Enterprise Solutions and Industrial Automation businesses with Analogic Corporation. Leidos retains a 41.5% minority ownership stake in the JV, while Altaris affiliates hold 58.5% and majority board control.

Counterparty
Altaris, LLC

“This JV creates an American innovator with the technology, talent and scale to address rapidly evolving global security screening needs. Its launch also sharpens our focus on the growth engines driving our NorthStar 2030 strategy.”

Tom Bell, Leidos Chief Executive Officer

“The strategic combination of these two businesses into one reinforces our commitment to the important national security missions and markets we serve.”

Tom Bell, Leidos Chief Executive Officer
8:22 AM ET 8-K
Capacity Expansion Terawulf Inc. WULF

Terawulf Capacity Expansion

TeraWulf Inc. entered into amended agreements with Kentucky Power to double the contracted power capacity at its Muskie Data Campus from 500 MW to 1 GW. The agreement also accelerates the delivery timeline for the second 500 MW phase from 2030 to 2029 to meet high customer demand for AI and high-performance computing infrastructure.

Counterparty
Kentucky Power Company
Term
through 2029

“Customer interest in Muskie has been tremendous, and power availability is central to those conversations. Securing the next 500 MW and moving its planned delivery into 2029 gives us greater flexibility to meet prospective customers’ deployment needs.”

Paul Prager, Chairman and Chief Executive Officer of TeraWulf
8:21 AM ET 8-K
M&A Deal C. H. Robinson Worldwide, Inc. CHRW

C. H. Robinson Worldwide Signs $5.8B M&A Deal with RXO, Inc.

C.H. Robinson Worldwide, Inc. has entered into a definitive agreement to acquire RXO, Inc. in a stock-and-cash transaction with an implied value of $5.8 billion. The deal combines two major North American third-party logistics providers and is expected to generate $300 million in annual cost synergies within two years of closing. The transaction is expected to close in the first half of 2027, creating a combined company with an enterprise value of over $25 billion.

Value
$5.8B
Counterparty
RXO, Inc.
Earnings call
Oct 2, 2026, 8:00 AM ET

“This transaction is a natural next step in our transformation, allowing us to create a more scaled, resilient North American third-party logistics provider positioned to offer exceptional customer service and redefine the future of our industry.”

Dave Bozeman, C.H. Robinson President and Chief Executive Officer

“Joining C.H. Robinson represents an exciting next chapter for our company, our employees and our customers. We have built a strong business by staying relentlessly focused on our customers, operating with agility and delivering solutions that help them navigate an increasingly complex supply chain.”

Drew Wilkerson, RXO Chairman and Chief Executive Officer
8:20 AM ET 8-K
Loan & Debt Red Robin Gourmet Burgers Inc RRGB

Red Robin Gourmet Burgers $115M Debt Financing with JPMorgan Chase Bank, N.A.

Red Robin Gourmet Burgers completed a refinancing of its credit facility, entering into a new $115 million agreement consisting of a $90 million term loan and a $25 million revolving line of credit. The new facility matures in October 2031 and replaces a prior 2022 credit agreement, following the company's receipt of approximately $89.4 million in gross proceeds from refranchising transactions. The funds will be used to repay existing debt and support general corporate requirements under the company's 'First Choice Plan'.

Value
$115M
Counterparty
JPMorgan Chase Bank, N.A.
Term
5 years
8:20 AM ET 8-K
Loan & Debt Hudson Pacific Properties, L.P. HPP

Hudson Pacific Properties $200M Debt Financing

Hudson Pacific Properties has commenced a cash tender offer to repurchase up to $200 million in aggregate principal amount of its outstanding 3.950% Senior Notes due 2027 and 5.950% Senior Notes due 2028. The company intends to fund the repurchase using cash on hand and borrowings from its unsecured revolving credit facility.

Value
$200M
8:19 AM ET 8-K
Business Update DeFi Development Corp. DFDV

DeFi Development Business Update

DeFi Development Corp. reported that its Solana (SOL) treasury grew to approximately 2.56 million SOL as of October 2, 2026, representing an 11% increase since August 12. Preliminary Q3 estimates indicate double-digit growth in SOL per share and over 100% growth in NAV per share, driven by continued SOL accumulation and the deployment of its CHAD preferred stock dividend strategy.

8:17 AM ET 8-K
M&A Deal RXO, Inc. RXO

RXO Signs $5.8B M&A Deal with C.H. Robinson Worldwide, Inc.

RXO, Inc. has entered into a definitive agreement to be acquired by C.H. Robinson in a stock-and-cash transaction with an implied value of $5.8 billion. RXO stockholders can elect to receive $30.25 in cash, 0.1992 shares of C.H. Robinson stock, or a standard combination of both per share. The deal is expected to close in the first half of 2027 and create a combined logistics company with an enterprise value exceeding $25 billion.

Value
$5.8B
Counterparty
C.H. Robinson Worldwide, Inc.
Earnings call
Oct 2, 2026, 8:00 AM ET
8:08 AM ET 8-K
M&A Deal Benitec Biopharma Inc. BNTC

Benitec Biopharma M&A Deal with U.S. Food and Drug Administration

Benitec Biopharma provided a status and timeline update for its BB-301 program following a Type C meeting with the FDA. The company remains on track to initiate a pivotal study in mid-2027, with the final study design expected to be confirmed in Q1 2027 after the FDA reviews additional natural history data.

Counterparty
U.S. Food and Drug Administration
8:07 AM ET 8-K
Capital Raise Flex Ltd. FLEX

Flex Capital Raise of $2B

Flex Ltd. entered into an agreement to sell $2.0 billion of Series A Convertible Preferred Stock in its Cloud and Power Infrastructure subsidiary, Axiom Solutions International, to a group led by General Catalyst and Koch Equity Development. The proceeds will fund Axiom's acquisition of EPC Power Corp and support its balance sheet ahead of a planned spin-off into an independent public company in Q1 2027. Flex is guaranteeing the investment, which includes a redemption obligation if the spin-off is not completed by the end of 2027.

Value
$2B
Counterparty
General Catalyst

“This investment provides equity funding for our recently announced acquisition of EPC Power and will allow Axiom to have a strong balance sheet as we prepare to stand up as an independent, publicly traded company squarely focused on the power, thermal, and compute infrastructure the AI era demands.”

Revathi Advaithi, Chief Executive Officer of Flex and expected Chief Executive Officer of Axiom

“Axiom sits at the center of the power and infrastructure buildout that AI demands, and we’ve been impressed by the team’s execution and the scale of the opportunity ahead.”

Hemant Taneja, Chief Executive Officer, General Catalyst
8:06 AM ET 8-K
Loan & Debt FTC Solar, Inc. FTCI

FTC Solar $5M Debt Financing with Acquiom Agency Services LLC

FTC Solar entered into a third amendment and limited waiver to its credit agreement, deferring a $5 million principal repayment from September 2026 to March 2027. The amendment also waives financial covenants for the remainder of 2026 and establishes new minimum revenue and EBITDA targets starting in Q1 2027. These changes provide the company with increased financial flexibility to execute its growth strategy.

Value
$5M
Counterparty
Acquiom Agency Services LLC
8:06 AM ET 8-K
Business Update Stablecoin Development Corp SDEV

Stablecoin Development Business Update

Stablecoin Development Corporation provided a preliminary update on its digital asset holdings and balance sheet for the quarter ended September 30, 2026. The company reported holding approximately 2.32 billion SKY tokens with a fair value of $180.2 million and a cash balance of $7.2 million. The update highlights the company's ongoing strategy of staking SKY tokens within the Sky Protocol, earning 34.6 million tokens in rewards during the quarter.

8:05 AM ET 8-K
Regulatory Approval Tela Bio, Inc. TELA

Tela Bio Regulatory Approval

TELA Bio received FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. This marks a significant milestone as it is the first fully resorbable synthetic product in the company's portfolio to be designed and produced in-house.

“FDA 510(k) clearance is a significant milestone for TELA Bio as Liora is the first fully resorbable synthetic product in our portfolio to be designed and produced in-house by our team of innovative engineers.”

Heather Getz, CEO of TELA Bio
8:05 AM ET 8-K
Partnership Forum Markets Inc FRMM

Forum Markets Partnership with Edge Node Inc.

Forum Markets and Edge Node Inc. formed a joint venture, Forum Edge AI LLC, to deploy and operate high-performance inference AI compute infrastructure across the U.S. Forum holds a 51% controlling interest in the JV, which will utilize existing data centers and mobile communications tower sites to provide GPU capacity to long-term offtake partners.

Counterparty
Edge Node Inc.
8:04 AM ET 8-K
Executive Compensation Butterfly Network, Inc. BFLY

Butterfly Network Executive Compensation

Butterfly Network appointed Michael Noonen to its Board of Directors and its Compensation and Technology Committees, effective October 9, 2026. In connection with his appointment, Noonen will receive an initial grant of restricted stock units (RSUs) valued at $300,000, which will vest over three years. Noonen is a seasoned semiconductor executive who previously served as CEO of Swave Photonics and MixComm.

Counterparty
Michael Noonen
Term
until next annual meeting
8:02 AM ET Form 4
Insider Selling NXP Semiconductors N.V. NXPI

NXP Semiconductors EVP, Chief People Officer Christopher L. Jensen Sells $805K of Stock

Christopher L. Jensen, EVP, Chief People Officer, sold 3,355 shares of NXP Semiconductors N.V. at $240.00 a share, worth $805K in total on Oct 1, 2026. Shares held after the trade: 288 (-92.1%).

Value
$805K
Shares
3,355
Price
$240.00
Role
EVP, Chief People Officer
Holding change
-92.1%
Trade date
Oct 1, 2026
8:01 AM ET 8-K
Clinical Trial Data Vaxcyte, Inc. PCVX

Vaxcyte Clinical Trial Data

Vaxcyte announced positive topline results from its OPUS-1 pivotal Phase 3 trial of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate for adults. The trial met all prespecified primary immunogenicity and safety endpoints, demonstrating noninferiority to Prevnar 20 and Capvaxive. These results will support a planned Biologics License Application (BLA) submission to the FDA in the first half of 2028.

Earnings call
Oct 5, 2026, 8:00 AM ET
8:01 AM ET 8-K
Investor Presentation SS Innovations International, Inc. SSII

SS Innovations International Investor Presentation

SS Innovations International, Inc. (SSII) filed an updated October 2026 Company Presentation to be used in communications with shareholders and the investment community. The presentation highlights the company's proprietary surgical robotic system, the SSi Mantra 3, and its vision for affordable surgical robotic solutions.

8:01 AM ET 8-K
Reverse Stock Split Jasper Therapeutics, Inc. JSPR

Jasper Therapeutics Reverse Stock Split

Jasper Therapeutics stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-15 and 1-for-35. Stockholders also approved increasing the total number of authorized shares of common stock from 490 million to 675 million.

8:01 AM ET 8-K
Business Update Rezolute, Inc. RZLT

Rezolute Business Update

Rezolute announced that the FDA recommended a pre-BLA meeting for ersodetug in congenital hyperinsulinism (HI) following a review of Phase 3 sunRIZE data. Although the trial missed its primary and key secondary endpoints, the Agency encouraged the meeting as a precursor to a potential Biologics License Application (BLA) submission. The company is also awaiting Phase 3 upLIFT results in tumor HI this quarter to finalize its overall regulatory strategy.

Counterparty
FDA

“We appreciate FDA’s thorough review of the extensive body of data generated in sunRIZE and are encouraged by the Agency’s recognition that this data will require in-depth evaluation during a formal BLA review.”

Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute
8:00 AM ET 8-K
Other 8-K Filing Quality Industrial Corp. QIND

Quality Industrial Other 8-K Filing

Quality Industrial Corp. filed Second Amended and Restated Articles of Incorporation, which increased the authorized common stock from 450 million to 1 billion shares. The amendment also grants the Board of Directors the authority to sell or exchange substantially all of the company's assets without stockholder approval and expands liability protection to include officers. These changes were approved by Fusion Fuel Green PLC, which holds approximately 51.9% of the company's voting power.

8:00 AM ET 8-K
Capital Raise Strategy Inc MSTR

Strategy Capital Raise of $15.7M

Strategy Inc reported that between October 1 and October 4, 2026, it sold 92,894 shares of Class A Common Stock under its at-the-market (ATM) offering program for net proceeds of $15.7 million. The company utilized these proceeds, along with existing cash, to acquire 334 additional bitcoins for approximately $28.7 million, bringing its total holdings to 848,000 bitcoins.

Value
$15.7M
8:00 AM ET 8-K
Business Update Strive, Inc. ASST

Strive Business Update

Strive, Inc. provided an operational update disclosing that it purchased 2,000 bitcoin between September 28 and October 2, 2026, at an average price of $84,422 per bitcoin. As of September 30, 2026, the company held 28,000 bitcoin with a fair value of approximately $2.34 billion and total treasury value of $2.68 billion. The filing also updated the company's cash position and share counts for its Class A, Class B, and Series A Perpetual Preferred stock.

7:46 AM ET 8-K
M&A Deal Distribution Solutions Group, Inc. DSGR

Distribution Solutions Group Signs $700M M&A Deal with LKCM Headwater Investments, LLC

Distribution Solutions Group (DSG) announced a $700 million senior notes offering to fund its previously announced merger with affiliates of LKCM Headwater Investments. Under the deal, LKCM Headwater will acquire all outstanding shares of DSG it does not already own for $35.00 per share in cash, taking the company private.

Value
$700M
Counterparty
LKCM Headwater Investments, LLC
7:36 AM ET 8-K
M&A Deal Matador Resources Co MTDR

Matador Resources Signs $1.27B M&A Deal with Paloma Permian, LLC

Matador Resources Company completed its acquisition of Paloma Permian, LLC for a cash purchase price of $1.275 billion. The deal adds approximately 16,500 net acres and over 156 net drilling locations in the Delaware Basin (Eddy and Lea Counties, New Mexico). Matador paid an as-adjusted closing price of $1.255 billion and expects to integrate the assets into its existing upstream and midstream operations.

Value
$1.27B
Counterparty
Paloma Permian, LLC
7:32 AM ET 8-K
M&A Deal Harrow, Inc. HROW

Harrow Signs $30M M&A Deal with Viatris Inc.

Harrow, Inc. completed the acquisition of the dry eye disease treatment TYRVAYA from Viatris for $30 million in cash at closing. The deal includes worldwide rights except for Japan, where Viatris will pay Harrow royalties on future sales. Harrow may also pay up to $70 million in contingent milestone payments based on net sales thresholds through 2029.

Value
$30M
Counterparty
Viatris Inc.
7:23 AM ET 8-K
M&A Deal PTC Inc. PTC

PTC Signs $22.6B M&A Deal with Schneider Electric SE

PTC Inc. has entered into a definitive agreement to be acquired by Schneider Electric SE for $205 per share in an all-cash transaction. The deal values PTC's equity at approximately $22.6 billion and will result in PTC becoming a wholly owned subsidiary of Schneider Electric, creating a scaled industrial software and AI franchise.

Value
$22.6B
Counterparty
Schneider Electric SE
Earnings call
Oct 5, 2026, 9:00 AM ET

“The acquisition of PTC represents an important step forward in our ambition to lead the new era of Energy and Industrial Intelligence. Together, we are creating the industry’s most complete Software & AI powerhouse and highest-quality portfolio bridging the physical and digital worlds.”

Olivier Blum, Chief Executive Officer of Schneider Electric

“Joining Schneider Electric is an incredible opportunity to elevate the scope and impact of what we deliver for our customers globally. We gain substantial scale and resources to accelerate innovation, advance our Intelligent Product Lifecycle vision, and expand our business into more geographies and end markets to serve more customers.”

Neil Barua, President and CEO of PTC
7:21 AM ET 8-K/A
M&A Deal Processa Pharmaceuticals, Inc. PCSA

Processa Pharmaceuticals M&A Deal with Vidya Therapeutics, Inc.

Processa Pharmaceuticals filed an amendment to its 8-K to provide audited financial statements and pro forma information following its acquisition of Vidya Therapeutics. The deal adds VT7208, a CNS-penetrant BTK inhibitor, to Processa's pipeline for the treatment of autoimmune conditions like multiple sclerosis and food allergies.

Counterparty
Vidya Therapeutics, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.